Central London’s private healthcare market is entering a more nuanced phase of its post‑pandemic cycle. Growth has not disappeared, but the easy gains of the Covid rebound have passed, leaving operators to navigate a landscape shaped by maturing PMI demand, price‑led self‑pay, and geopolitically exposed international flows. Few observers track these dynamics as closely as Ted Townsend, whose Central London Private Healthcare Report 2026 continues the analytical tradition he established during his more-than 12 years as a market analyst producing his Private Acute Healthcare Central London Market Reports and conference director. Prior to analysing developments in Central London’s private healthcare sector, he worked as business development manager for Reed and Diageo. He also spent time with Lazard and Bain & Co.
Nick Herbert, editor of Investors in Healthcare, caught up with Townsend to discover what the latest data shows: a market normalising faster than expected; a sharper three‑way split in business models; and a competitive environment where strategic clarity matters more than ever.
Investors in Healthcare: What does the data tell us about how demand for Central London Private Healthcare is evolving across PMI, self-pay and international patient segments?
Ted Townsend: If you stand back from the noise, the picture is of a market that is still growing, but normalising.
PMI remains the engine of the Central London market. Growth is still respectable but the post‑Covid “boom” is clearly over. As I note in the report, the three main drivers – number of people with PMI, the percentage who claim, and what they claim for – all seem to have levelled out as employers and insurers seek to restrict access in order to contain premiums and claims.
Self‑pay has flattened off. Nominal growth is largely a price story rather than a volume story. Real demand is under pressure from weaker consumer confidence, particularly among the over‑50s who are both more likely to need care and to pay for it privately.
International (Embassy) volumes have been the most volatile. After a difficult 2024, driven in particular by Kuwait stepping back from London, I’m forecasting a modest recovery. But this is a politically exposed revenue stream. The report was finalised in the midst (or just the beginning?) of the US and Israeli bombing and other attacks on Iran with likely impacts on Embassy patients returning to the London private healthcare market.
That geopolitical overlay means the mix between payors is likely to remain fluid at the margin, even if the broad shares are relatively stable.
So yes, there are shifts, but they are more about the quality and reliability of growth than dramatic swings in market share. PMI is maturing, self‑pay is price‑led, and Embassy work is a risk‑on, risk‑off component rather than a structural growth story.
IIH: What are the most surprising trends in terms of utilisation, pricing or specialty mix?
TT: Two things stand out to me: the speed with which PMI growth has decelerated, and the way the market is sorting itself into three quite distinct business models.
On utilisation, the headline numbers still look healthy. The surprise is not that growth has slowed – that was inevitable – but how quickly the system has moved from catch‑up mode to something closer to trend.
On pricing, self‑pay is increasingly a story of Average Revenue per Case (ARPC) rather than volume. As I put it in the report: Self‑Pay patients are flat to declining, with growth really only coming from increasing ARPC (in other words, price rises).
That is not a sustainable strategy indefinitely, particularly against a backdrop of weak confidence among older consumers and higher mortgage and living costs.
The most interesting structural trend is the “trifurcation” of the market. Full‑service hospitals with genuine higher‑acuity capability in selected specialties are doing well. High‑throughput day‑case centres – often very focused, very efficient – are also performing strongly. In the middle sit a number of hospitals doing low‑to‑medium complexity work with one‑ or two‑night stays; they are showing positive but not very attractive growth and finding it harder to attract consultants.
That three‑way split is becoming more pronounced, and it has real implications for capital allocation and strategy.
IIH: Does the growth in self-pay still have momentum, or are affordability pressures and insurer dynamics having an impact?
TT: The short answer is that self‑pay has lost most of its cyclical momentum and is now grinding forward, supported by price rather than volume.
The Covid‑era narrative was that long NHS waiting lists would permanently reset self‑pay demand. What we’re actually seeing is a more nuanced picture. Waiting lists matter, but they are not the dominant driver. Consumer confidence is more important than waiting list times for the decisions of Self‑Pay patients to go private.
Affordability pressures are clearly biting. Higher interest rates, energy costs and general inflation all compete with discretionary medical spend, even for relatively affluent households. At the same time, insurers have tightened up PMI access and benefit design, which has two effects: it caps PMI‑funded volumes, but it also limits the “spillover” of patients who might otherwise have gone self‑pay if PMI were more generous.
In my forecasts, the growth rate in self‑pay will slow. Operators who built business cases on a permanently elevated self‑pay curve will need to revisit their assumptions.
IIH: How competitive is the central London market in terms of capacity expansion, consultant recruitment and investment strategies?
TT: Central London remains one of the most competitive private healthcare markets in the world. You have a dense cluster of incumbent operators, a steady stream of new capacity and a growing presence of international brands – all chasing a finite pool of consultants and patients.
On capacity, the pipeline is still significant even as demand growth moderates: HCA is adding beds and diagnostics, and opening a new outpatient and diagnostic clinic at Paternoster Square; Cleveland Clinic is committing to a cancer centre; One Welbeck‑style ambulatory models are being replicated; and even niche players like Fortius are squeezing more out of their footprint.
Consultant recruitment and alignment are becoming the critical battleground. Models that offer equity participation in theatres, imaging or specialty platforms are a direct response to that. They are as much about locking in consultant loyalty as they are about operational efficiency.
On investment strategy, we’re seeing a mix of defensive and offensive moves. Bupa’s acquisition of King Edward VII, following New Victoria, is partly about securing a provider footprint and partly about creating a counterweight to HCA in the Harley Street area. Nuffield’s exit from St Bartholomew’s, by contrast, is recognition that not every new build will work in a slower‑growth environment.
All of this points to further consolidation over time. The market is separating into well‑capitalised, full‑service platforms; highly efficient day‑case and specialty centres; and a tail of sub‑scale, mid‑market hospitals under margin pressure. In that context, I would expect more M&A, more strategic partnerships between UK and overseas operators, and potentially some closures or repurposing of weaker assets.
IIH: What should investors and operators be watching for 2026 and 2027?
TT: For investors and operators, I’d highlight five things to watch: the boom in PMI is over and future growth will be driven more by pricing and case mix than by big increases in membership or claim rates; for self‑pay, macro sentiment among older, asset‑owning households is critical; geopolitics is a genuine swing factor; and with multiple new facilities coming onstream, the risk is that supply runs ahead of sustainable demand in certain niches or locations.
The most important strategic question for any operator is: which of the three emerging models are you really in? High‑acuity, full‑service; high‑volume day‑case; or mid‑market overnight? The first two can justify continued investment and should capture a disproportionate share of growth. The third will face increasing pressure to consolidate, specialise or exit.
